Fennec Pharmaceuticals
FENC
53 hedge funds and large institutions have $108M invested in Fennec Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 7 closing their positions.
337% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $355K
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
82% more capital inflows, than outflows
Capital inflows: $11.4M | Capital outflows: $6.3M
23% more funds holding
Funds holding: 43 → 53 (+10)
1.9% more ownership
Funds ownership: 47.42% → 49.31% (+1.9%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DG Capital Management
New York
|
+$2.12M |
| 2 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$1.5M |
| 3 |
Harbert Fund Advisors
Birmingham,
Alabama
|
+$1.39M |
| 4 |
GJL
Gendell Jeffrey L
|
+$920K |
| 5 |
Millennium Management
New York
|
+$582K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$2.61M |
| 2 |
EAM Investors
Solana Beach,
California
|
-$1.69M |
| 3 |
TA
Tamarack Advisers
Carlsbad,
California
|
-$592K |
| 4 |
Tamar Securities
Woodland Hills,
California
|
-$513K |
| 5 |
Two Sigma Investments
New York
|
-$253K |
FENC Hedge Fund Activity: Q1 2023 in Review
53 of the 6,289 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q1 2023, worth a combined $108M — down 9.2% from $120M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new FENC positions and 7 closed out — a net gain of 10 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was DG Capital Management, adding an estimated $2.12M. The largest seller was Opaleye Management, exiting entirely with an estimated $2.61M sold.
- 53 institutional investors held Fennec Pharmaceuticals (FENC) as of Q1 2023, up from 43 in Q4 2022.
- Funds reported $108M of Fennec Pharmaceuticals stock for Q1 2023, down 9.2% quarter-over-quarter.
- 17 funds opened new Fennec Pharmaceuticals positions in Q1 2023 and 7 closed out, a net change of +10 holders.
- The largest Fennec Pharmaceuticals buyer in Q1 2023 was DG Capital Management, an estimated $2.12M added.
- The largest Fennec Pharmaceuticals seller in Q1 2023 was Opaleye Management, an estimated $2.61M sold.
Based on aggregated 13F filings for Q1 2023.